Phase i dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer

Yeul Hong Kim, Hee Yeon Seo, Yoon Tae Jeen, Hoon K. Kim, Byoung Yong Shim, Jinmo Yang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background The primary objectives of this study were to estimate the maximum-tolerated dose (MTD) of docetaxel in combination with a fixed dose of S-1 and to determine the recommended dose (RD). Patients and methods Patients with histologically proven gastric carcinoma with metastatic or locally advanced inoperable disease were eligible. Patients received intravenous docetaxel starting at 40 mg/m2 (dose level 1), and stepwise dose increases to 50, 60, and 70 mg/m2 were planned for successive patient cohorts (dose levels 2, 3, and 4, respectively) over 1 h on day 1 and oral S-1 administered at a fixed dose of 40 mg/m2 twice daily on days 1-14, both drugs every 21 days. Results A total of 13 patients were enrolled into this trial. All three patients at dose level 3 developed dose-limiting toxicities (DLT), and this level was declared to be the MTD. Hence, level 2 (docetaxel 50 mg/m2) was declared to be the RD for the next study. As 9 of the 13 enrolled patients responded to treatment, the overall objective response rate was 69.2% (95% CI, 44.1-94.3%). The median time to progression was 8.38 months (range 1.44-8.51) and the overall survival duration was 9.9 months (range 0.62-11.57). The most common grade 3/4 toxicity of docetaxel plus S-1 was neutropenia, which was tolerable and manageable. Conclusion This regimen showed encouraging activity and a manageable safety profile in advanced gastric carcinoma and could be used in further randomized studies.

Original languageEnglish
Pages (from-to)253-260
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume63
Issue number2
DOIs
Publication statusPublished - 2009 Jan 1

Fingerprint

docetaxel
Chemotherapy
Combination Drug Therapy
Stomach Neoplasms
Toxicity
Maximum Tolerated Dose
Stomach
Carcinoma
S 1 (combination)
Neutropenia
Pharmaceutical Preparations

Keywords

  • Clinical trial
  • Combination chemotherapy
  • Docetaxel
  • Gastric neoplasm
  • Phase I
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology (medical)
  • Pharmacology
  • Toxicology

Cite this

Phase i dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer. / Kim, Yeul Hong; Seo, Hee Yeon; Jeen, Yoon Tae; Kim, Hoon K.; Shim, Byoung Yong; Yang, Jinmo.

In: Cancer Chemotherapy and Pharmacology, Vol. 63, No. 2, 01.01.2009, p. 253-260.

Research output: Contribution to journalArticle

@article{b747dd18dec04562bb4dad6eb1035ad7,
title = "Phase i dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer",
abstract = "Background The primary objectives of this study were to estimate the maximum-tolerated dose (MTD) of docetaxel in combination with a fixed dose of S-1 and to determine the recommended dose (RD). Patients and methods Patients with histologically proven gastric carcinoma with metastatic or locally advanced inoperable disease were eligible. Patients received intravenous docetaxel starting at 40 mg/m2 (dose level 1), and stepwise dose increases to 50, 60, and 70 mg/m2 were planned for successive patient cohorts (dose levels 2, 3, and 4, respectively) over 1 h on day 1 and oral S-1 administered at a fixed dose of 40 mg/m2 twice daily on days 1-14, both drugs every 21 days. Results A total of 13 patients were enrolled into this trial. All three patients at dose level 3 developed dose-limiting toxicities (DLT), and this level was declared to be the MTD. Hence, level 2 (docetaxel 50 mg/m2) was declared to be the RD for the next study. As 9 of the 13 enrolled patients responded to treatment, the overall objective response rate was 69.2{\%} (95{\%} CI, 44.1-94.3{\%}). The median time to progression was 8.38 months (range 1.44-8.51) and the overall survival duration was 9.9 months (range 0.62-11.57). The most common grade 3/4 toxicity of docetaxel plus S-1 was neutropenia, which was tolerable and manageable. Conclusion This regimen showed encouraging activity and a manageable safety profile in advanced gastric carcinoma and could be used in further randomized studies.",
keywords = "Clinical trial, Combination chemotherapy, Docetaxel, Gastric neoplasm, Phase I, S-1",
author = "Kim, {Yeul Hong} and Seo, {Hee Yeon} and Jeen, {Yoon Tae} and Kim, {Hoon K.} and Shim, {Byoung Yong} and Jinmo Yang",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s00280-008-0734-6",
language = "English",
volume = "63",
pages = "253--260",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase i dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer

AU - Kim, Yeul Hong

AU - Seo, Hee Yeon

AU - Jeen, Yoon Tae

AU - Kim, Hoon K.

AU - Shim, Byoung Yong

AU - Yang, Jinmo

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background The primary objectives of this study were to estimate the maximum-tolerated dose (MTD) of docetaxel in combination with a fixed dose of S-1 and to determine the recommended dose (RD). Patients and methods Patients with histologically proven gastric carcinoma with metastatic or locally advanced inoperable disease were eligible. Patients received intravenous docetaxel starting at 40 mg/m2 (dose level 1), and stepwise dose increases to 50, 60, and 70 mg/m2 were planned for successive patient cohorts (dose levels 2, 3, and 4, respectively) over 1 h on day 1 and oral S-1 administered at a fixed dose of 40 mg/m2 twice daily on days 1-14, both drugs every 21 days. Results A total of 13 patients were enrolled into this trial. All three patients at dose level 3 developed dose-limiting toxicities (DLT), and this level was declared to be the MTD. Hence, level 2 (docetaxel 50 mg/m2) was declared to be the RD for the next study. As 9 of the 13 enrolled patients responded to treatment, the overall objective response rate was 69.2% (95% CI, 44.1-94.3%). The median time to progression was 8.38 months (range 1.44-8.51) and the overall survival duration was 9.9 months (range 0.62-11.57). The most common grade 3/4 toxicity of docetaxel plus S-1 was neutropenia, which was tolerable and manageable. Conclusion This regimen showed encouraging activity and a manageable safety profile in advanced gastric carcinoma and could be used in further randomized studies.

AB - Background The primary objectives of this study were to estimate the maximum-tolerated dose (MTD) of docetaxel in combination with a fixed dose of S-1 and to determine the recommended dose (RD). Patients and methods Patients with histologically proven gastric carcinoma with metastatic or locally advanced inoperable disease were eligible. Patients received intravenous docetaxel starting at 40 mg/m2 (dose level 1), and stepwise dose increases to 50, 60, and 70 mg/m2 were planned for successive patient cohorts (dose levels 2, 3, and 4, respectively) over 1 h on day 1 and oral S-1 administered at a fixed dose of 40 mg/m2 twice daily on days 1-14, both drugs every 21 days. Results A total of 13 patients were enrolled into this trial. All three patients at dose level 3 developed dose-limiting toxicities (DLT), and this level was declared to be the MTD. Hence, level 2 (docetaxel 50 mg/m2) was declared to be the RD for the next study. As 9 of the 13 enrolled patients responded to treatment, the overall objective response rate was 69.2% (95% CI, 44.1-94.3%). The median time to progression was 8.38 months (range 1.44-8.51) and the overall survival duration was 9.9 months (range 0.62-11.57). The most common grade 3/4 toxicity of docetaxel plus S-1 was neutropenia, which was tolerable and manageable. Conclusion This regimen showed encouraging activity and a manageable safety profile in advanced gastric carcinoma and could be used in further randomized studies.

KW - Clinical trial

KW - Combination chemotherapy

KW - Docetaxel

KW - Gastric neoplasm

KW - Phase I

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=57149129932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149129932&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0734-6

DO - 10.1007/s00280-008-0734-6

M3 - Article

VL - 63

SP - 253

EP - 260

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -